HSC Exam Practice

Sample response. An antigen is any molecule — typically a protein or polysaccharide — that can be recognised by the adaptive immune system and trigger a specific immune response; antigens are commonly found on the surfaces of pathogens such as viruses or bacteria. An epitope (or antigenic determinant) is the specific small region of an antigen that an antibody or B cell receptor actually binds to — it is a subset of the antigen molecule. A single antigen may carry multiple different epitopes, each capable of stimulating a different B cell clone.

Marking notes. 1 mark — antigen correctly defined as a molecule recognised by the immune system that triggers a specific response (must reference specificity or response, not just "foreign molecule"). 1 mark — epitope correctly defined as the specific binding region on an antigen. 1 mark — a clear distinction between antigen (whole molecule) and epitope (specific binding site within/on the antigen).

Sample response. The variable region is located at the tips of the two arms (Fab regions) of the Y-shaped antibody. Its unique three-dimensional shape allows it to bind one specific epitope — this is the basis of the antibody's specificity. Each antibody has two identical variable regions, giving it two antigen-binding sites. The Fc (constant) region forms the stem of the Y. It determines the antibody's class (e.g. IgG) and enables effector functions: phagocytes carry Fc receptors on their surface that bind this region, linking the pathogen to the phagocyte for engulfment (opsonisation); the Fc region also initiates complement activation.

Marking notes. 1 mark — variable region located at Fab tip; 1 mark — variable region function: unique shape, binds one specific epitope (specificity); 1 mark — Fc region located at the stem; 1 mark — Fc region function: enables effector functions (opsonisation via phagocyte Fc receptors, complement activation, or determines antibody class). Do not accept "the Fc region binds antigen" — that is the variable region's function.

Sample response. Clonal selection is the process by which one specific B cell is chosen for activation from a pool of millions of naive B cells, each carrying a unique B cell receptor (BCR). When an antigen is presented by a dendritic cell on MHC II, it is recognised by the single B cell whose BCR shape matches that antigen's epitope — this B cell binds the antigen via its BCR. Binding alone is insufficient for full activation; the B cell must also receive a co-stimulatory signal from a T helper (CD4+) cell that has independently recognised the same antigen fragment presented on MHC II. This two-signal requirement ensures that only genuine threats (recognised by two independent immune cell types) trigger a B cell response, preventing accidental activation against self-antigens.

Marking notes. 1 mark — clonal selection identified as activation of the one B cell (from millions of naive B cells) whose BCR matches the antigen (epitope specificity). 1 mark — T helper co-stimulatory signal correctly identified as required for full B cell activation. 1 mark — the two-signal requirement linked to prevention of activation against self-antigens (immune tolerance / safety mechanism).

Sample response. Plasma cells are short-lived effector B cells (days to weeks) that arise from clonal expansion of the selected B cell. Their role is to secrete thousands of identical antibodies per second, producing the immediate antibody response that clears the current infection. Memory B cells are long-lived lymphocytes (years to decades) that also arise from clonal expansion of the same selected B cell. They do not secrete antibodies during the current infection; instead they persist in lymph nodes and bone marrow, carrying the same BCR as the original selected B cell, and activate rapidly on re-exposure to the same antigen, enabling the faster and stronger secondary immune response.

Marking notes. 1 mark — lifespan contrast: plasma cells short-lived (days to weeks); memory B cells long-lived (years to decades). 1 mark — plasma cell role: secretes large amounts of specific antibody during the current response. 1 mark — memory B cell role: persists and enables rapid, amplified secondary response on re-exposure.

Sample response. Neutralisation: antibodies bind to surface molecules on a bacterium (e.g. toxin proteins or adhesion molecules). By physically occupying these sites, the antibody prevents the bacterium or its toxin from binding to host cell receptors, stopping it from entering or damaging cells. Opsonisation: antibodies coat the bacterium's surface (variable regions binding to bacterial antigens). Phagocytes (neutrophils and macrophages) carry Fc receptors that bind the constant Fc region of the coating antibodies, anchoring the bacterium tightly to the phagocyte. This dramatically increases phagocytosis efficiency — the bacterium is engulfed and destroyed by digestive enzymes inside the phagolysosome. Accept also: agglutination (antibodies cross-link multiple bacteria into clumps) or complement activation (Fc region triggers the complement cascade, producing membrane attack complexes).

Marking notes. 1 mark per mechanism correctly named (max 2). 1 mark per mechanism correctly described — what the antibody does AND how it leads to pathogen elimination (max 2). Four marks total. Naming alone without explanation scores 1 per mechanism (max 2). Do not accept "kills the bacterium directly" as a mechanism.

Sample response. B cells binding antigen via their BCR receive signal 1 (antigen recognition) but this alone is insufficient to trigger full clonal expansion. Signal 2 is the co-stimulatory signal delivered by a T helper (CD4+) cell that has independently recognised a fragment of the same antigen presented on MHC II by a dendritic cell. The T helper cell binds the B cell and releases cytokines that fully activate it. This two-signal requirement protects the body by ensuring that only genuine pathogens — recognised independently by two different types of immune cell — trigger a B cell response. A self-antigen might accidentally bind a B cell's BCR (signal 1), but it is unlikely to simultaneously activate the T helper pathway (signal 2), so the B cell is not activated against self-tissue. This mechanism is therefore a key safeguard against autoimmune disease.

Marking notes. 1 mark — T helper co-stimulatory signal is required in addition to BCR–antigen binding for B cell activation. 1 mark — T helper cell itself recognises the same antigen (on MHC II) independently. 1 mark — explains why this protects the body: prevents accidental activation against self-antigens (immune tolerance; autoimmune safeguard). HIV connection (T helper cell depletion prevents B cell responses) is acceptable for the third mark if correctly applied.

Sample response (a). During the primary series (months 2–6, three doses), IgG antibody levels rise gradually but remain low — reaching a modest peak of approximately 0.5 IU/mL by approximately month 8, then declining to near-baseline levels by month 18. This contrasts with the booster dose at month 18, which produced a rapid rise to approximately 4.5 IU/mL — a 9-fold increase over the primary peak — achieved much more quickly (within 4–6 weeks of the booster).

Marking notes (a). 1 mark — correctly identifies that primary series produces a low, slowly rising antibody titre (~0.5 IU/mL) that declines before the booster. 1 mark — correctly identifies that the booster at month 18 produced a much higher peak (~4.5 IU/mL) rapidly; or computes/estimates the ratio (≥9-fold). Both data points or the comparison required.

Sample response (b). The primary series introduced tetanus toxoid antigens to a naive immune system. Clonal selection was required to identify the rare B cell clone from millions of naive B cells whose BCR matched the tetanus toxoid epitope — a slow process taking days to weeks. The three primary doses gradually expanded the responding clone, but the peak antibody titre was modest (~0.5 IU/mL) because naive B cells require time to be selected, activated, and expanded. After the primary series, clonal expansion also produced memory B cells specific for tetanus toxoid antigens. By month 18 when the booster was given, these memory B cells were present in much larger numbers than the original naive clone and were already pre-selected for the tetanus toxoid epitope. The booster re-exposed them to the same antigen, triggering a rapid secondary response: memory B cells activated within hours, differentiating quickly into plasma cells producing large amounts of high-affinity IgG, reaching ~4.5 IU/mL — approximately 9× the primary peak — and achieving it far more quickly.

Marking notes (b). 1 mark — correctly identifies the primary series as a primary response from naive B cells requiring clonal selection. 1 mark — correctly identifies memory B cells as the basis of the amplified booster response. 1 mark — explains that memory B cells do not require a new round of clonal selection and activate more rapidly. 1 mark — links the higher antibody titre to the larger pool of pre-selected memory cells / greater clonal expansion capacity.

Sample response (c). Each booster dose acts as a new exposure to the tetanus toxoid antigen. After each exposure, clonal expansion produces not only more plasma cells (creating the antibody peak) but also more memory B cells. The second booster at month 48 therefore activated a pool of memory B cells that had been enlarged by two previous rounds of clonal expansion (primary series + first booster), rather than just one. A larger pool of memory B cells can differentiate into more plasma cells simultaneously, producing a higher antibody peak (6.8 vs 4.5 IU/mL).

Marking notes (c). 1 mark — recognises that each round of clonal expansion adds memory B cells to the pool. 1 mark — correctly applies this to explain the increasing peak heights: more memory cells available at each booster → higher antibody peak. Accept reference to "affinity maturation" (IgG produced by B cells after repeated antigen exposure tends to have higher affinity) as an alternative or additional mechanism for 1 mark.

Sample response. The claim that childhood chickenpox confers lifelong immunity is well-supported by immunological evidence. When varicella-zoster virus (VZV) infects a child, dendritic cells present VZV antigen fragments on MHC II. Clonal selection identifies the B cell clone whose BCR matches the VZV epitope from millions of naive B cells. Clonal expansion then produces plasma cells — secreting IgG antibodies that clear the infection — and long-lived memory B cells specific for VZV antigens. These memory B cells persist in lymph nodes and bone marrow for decades, carrying the same BCR as the original selected clone. On re-exposure to VZV (which has stable surface antigens — its envelope glycoproteins do not mutate significantly from year to year), memory B cells activate within hours and differentiate into plasma cells that flood the bloodstream with IgG within 1–3 days — eliminating the virus before it can establish a significant infection. The person typically experiences no symptoms. This mechanism satisfactorily explains lifelong protection against VZV.

The same mechanisms — clonal selection generating memory B cells, which enable a faster and stronger secondary response on re-exposure — underlie influenza A immunity. However, the extent to which they provide lifelong protection against influenza is fundamentally limited by antigenic variation. Influenza A mutates its key surface antigens — particularly haemagglutinin (HA) and neuraminidase (NA) — through a process called antigenic drift: gradual accumulation of mutations in the genes encoding these proteins. Because BCRs and antibodies are highly specific — their variable regions bind a particular epitope with a specific shape — a mutated HA protein may present epitopes sufficiently different that existing memory B cells (selected against a previous strain's HA) no longer recognise them. When this occurs, the immune system must mount an essentially primary response against the new variant: clonal selection from naive B cells, with the associated 7–14 day lag and modest initial antibody titre. Clinical illness occurs while this primary response is being established. This is exactly the pattern observed in population studies — memory B cells formed after infection or vaccination against one influenza season's strain may provide poor protection against the next season's dominant strain if its HA has drifted sufficiently.

The fundamental difference between VZV and influenza A therefore lies not in the mechanism of adaptive immunity — which is identical — but in the stability of the antigen that memory targets. VZV's stable antigens mean that once a memory B cell clone is selected, it remains relevant for life. Influenza A's annually drifting antigens mean the existing memory B cell repertoire progressively loses relevance as the virus evolves. Annual influenza vaccination is necessary because each new season's dominant strain may present novel epitopes requiring a new primary-level clonal selection event — unless a vaccine introduces those epitopes first, generating matched memory B cells before the season begins. The claim of lifelong immunity against chickenpox is therefore well-justified; the same degree of lasting protection does not apply to influenza A due to antigenic drift.

Marking criteria.

• 1 mark — VZV immunity mechanism correctly described: clonal selection of specific BCR-matched B cell → clonal expansion → plasma cells + long-lived memory B cells specific for VZV antigens.
• 1 mark — Memory B cell mechanism for lifelong protection: pre-existing, pre-selected, large pool; rapid activation on re-exposure (hours → plasma cells within 1–3 days); virus cleared before symptoms.
• 1 mark — Claim evaluated as well-supported for VZV specifically because VZV has stable surface antigens (envelope glycoproteins do not mutate significantly).
• 1 mark — The same adaptive immune mechanisms operate for influenza A (clonal selection, memory B cells), but apply correctly that influenza A undergoes antigenic drift — mutation of HA and/or NA surface antigens.
• 1 mark — Explains why antigenic drift undermines memory: mutated HA epitopes are no longer recognised by existing memory BCRs, effectively requiring a new primary response.
• 1 mark — Distinguishes VZV from influenza A on the basis of antigen stability (not mechanism) — correctly identifying this as the key difference, not the adaptive immunity process itself.
• 1 mark — Reaches an explicit evaluative conclusion: lifelong protection against VZV is well-justified; this does not extend to influenza A due to antigenic drift; links annual vaccination to the need for new matched memory cells for each season's variant.